Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Heath

Showing results (151-160 of 248) with videos related to

Pageof 25
Sort By:
Cancer Medicine|December 21, 2022
Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT studySusan Eggly, Nicole Senft, Seongho Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancerElisabeth I Heath, David W Hillman, Ulka Vaishampayan, et al.
Croatian Medical Journal|May 16, 2000
Joining together to combat povertyI Heath, A Haines, Z Malenica, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2024
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancerUlka N Vaishampayan, Marianne Keessen, Robert Dreicer, et al.
Kidney Cancer (Clifton, Va.)|November 26, 2019
Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)Timothy W Synold, Melissa Plets, Catherine M Tangen, et al.
The Lancet. Oncology|April 3, 2023
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 studyToni K Choueiri, David F McDermott, Jaime Merchan, et al.
JNCI Cancer Spectrum|April 5, 2019
The Epidemiology of Cancer Among Homeless Adults in Metropolitan DetroitAndreana N Holowatyj, Elisabeth I Heath, Lisa M Pappas, et al.
Investigational New Drugs|February 7, 2019
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancerDeaglan McHugh, Mario Eisenberger, Elisabeth I Heath, et al.
JAMA Oncology|September 17, 2020
Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate CancerNicole Senft, Lauren M Hamel, Mark A Manning, et al.
JAMA Network Open|January 26, 2021
Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical TrialUlka N Vaishampayan, Lance K Heilbrun, Paul Monk, et al.
Pageof 25

Showing results (151-160 of 248) with videos related to

Sort By:
Pageof 25
Cancer Medicine|December 21, 2022
Addressing multilevel barriers to clinical trial participation among Black and White men with prostate cancer through the PACCT studySusan Eggly, Nicole Senft, Seongho Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancerElisabeth I Heath, David W Hillman, Ulka Vaishampayan, et al.
Croatian Medical Journal|May 16, 2000
Joining together to combat povertyI Heath, A Haines, Z Malenica, et al.
European Journal of Cancer (Oxford, England : 1990)|March 22, 2024
A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancerUlka N Vaishampayan, Marianne Keessen, Robert Dreicer, et al.
Kidney Cancer (Clifton, Va.)|November 26, 2019
Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)Timothy W Synold, Melissa Plets, Catherine M Tangen, et al.
The Lancet. Oncology|April 3, 2023
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 studyToni K Choueiri, David F McDermott, Jaime Merchan, et al.
JNCI Cancer Spectrum|April 5, 2019
The Epidemiology of Cancer Among Homeless Adults in Metropolitan DetroitAndreana N Holowatyj, Elisabeth I Heath, Lisa M Pappas, et al.
Investigational New Drugs|February 7, 2019
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancerDeaglan McHugh, Mario Eisenberger, Elisabeth I Heath, et al.
JAMA Oncology|September 17, 2020
Willingness to Discuss Clinical Trials Among Black vs White Men With Prostate CancerNicole Senft, Lauren M Hamel, Mark A Manning, et al.
JAMA Network Open|January 26, 2021
Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical TrialUlka N Vaishampayan, Lance K Heilbrun, Paul Monk, et al.
Pageof 25